Zahran Asmaa M, Rayan Amal, Saad Khaled, Rezk Khalid, Soliman Ahmed, Rizk Mohamed Ahmed, Mahros Aya Mohammed, Mahran Essam-Eldeen M O, Bashir Mohamed Ahmed, Elmasry Heba M, Zahran Zeinab Albadry M, Ibrahim Ahmed Khalid, Fageeh Mohsen M, Gamal Doaa A
Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
J Clin Med Res. 2024 Aug;16(7-8):363-374. doi: 10.14740/jocmr5201. Epub 2024 Jul 23.
The current study was conducted to explore the impact of macrophages and programmed cell death protein 1 (PD-1) expression on tumor-infiltrating lymphocytes (TILs) on treatment outcomes and to define the interaction between these factors and the clinicopathologic features of advanced cholangiocarcinoma (CCA) patients.
Twenty-five patients with metastatic CCA were recruited for the current study from El-Rajhi Hospital and the Clinical Oncology Department of Assiut University. Additionally, 19 healthy controls were included. Before the flow cytometric detection of immune cells, the diagnosis and staging of CCA were performed based on surgical intervention, imaging, carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) determinations. This was followed by flow cytometric detection of CD4, CD8, CD4PD-1, CD8PD-1, and CD11bCD68 macrophages in the peripheral blood of both patients and controls.
The current results revealed higher levels of CD4, CD8, and CD11bCD68 macrophages in controls compared to patients. At the same time, PD-1 expression was significantly higher in patients compared to controls. CD4 was correlated with improved progression-free survival (PFS), while CD8PD-1 was associated with shorter PFS. In general, CD4 and CD8 levels progressively increased with improved response to treatments, differentiation, single organ site metastasis, and surgical interventions. On the contrary, PD-1 expression and macrophages progressively increased with worsening response, dedifferentiation, multiple organ sites, and surgical interventions. The median PFS was 12 months, and the mean ± standard error (SE) was 13.1 ± 1.3.
CCA has a desmoplastic microenvironment with complex immunologic topography and tumor-reactive stroma. The immune landscape of the peripheral blood mononuclear cells (PBMCs) in CCA patients before treatment could reflect the state of systemic immune function and response to treatments. Our results revealed that T-lymphocytes correlated with better prognosis while macrophages and PD-1 expression were associated with poor outcomes.
本研究旨在探讨巨噬细胞和程序性细胞死亡蛋白1(PD-1)表达对肿瘤浸润淋巴细胞(TILs)治疗效果的影响,并确定这些因素与晚期胆管癌(CCA)患者临床病理特征之间的相互作用。
本研究从埃尔-拉吉医院和阿斯尤特大学临床肿瘤学系招募了25例转移性CCA患者。此外,纳入了19名健康对照者。在对免疫细胞进行流式细胞术检测之前,基于手术干预、影像学、糖类抗原19-9(CA19-9)和癌胚抗原(CEA)测定对CCA进行诊断和分期。随后对患者和对照者外周血中的CD4、CD8、CD4PD-1、CD8PD-1和CD11bCD68巨噬细胞进行流式细胞术检测。
目前的结果显示,与患者相比,对照者的CD4、CD8和CD11bCD68巨噬细胞水平更高。同时,患者的PD-1表达明显高于对照者。CD4与无进展生存期(PFS)改善相关,而CD8PD-1与较短的PFS相关。总体而言,随着对治疗的反应改善、分化、单器官部位转移和手术干预,CD4和CD8水平逐渐升高。相反,随着反应恶化、去分化、多器官部位和手术干预,PD-1表达和巨噬细胞逐渐增加。中位PFS为12个月,平均±标准误(SE)为13.1±1.3。
CCA具有促结缔组织增生的微环境,免疫地形复杂且有肿瘤反应性基质。治疗前CCA患者外周血单个核细胞(PBMCs)的免疫格局可反映全身免疫功能状态和对治疗的反应。我们的结果显示,T淋巴细胞与较好预后相关,而巨噬细胞和PD-1表达与不良预后相关。